HDAC inhibitors (Sophia Bioscience)

N/A

Report date: 2025/03/20 14:45:06
NME

Base Information

Drug NameHDAC inhibitors (Sophia Bioscience)
Drug Alias Namehistone deacetylase inhibitors (Sophia Bioscience)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionHistone deacetylase inhibitors
TargetsHistone deacetylase
Therapy Area/IndicationsProstatic NeoplasmsCarcinoma, Hepatocellular
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesSophia Bioscience Inc
China Registration ClassN/A

Develop Information

Active CompaniesSophia Bioscience Inc
Inactive CompaniesN/A
Active IndicationsCarcinoma, Hepatocellular
Inactive IndicationsProstatic Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A